<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367427">
  <stage>Registered</stage>
  <submitdate>14/11/2014</submitdate>
  <approvaldate>20/02/2015</approvaldate>
  <actrnumber>ACTRN12615000171516</actrnumber>
  <trial_identification>
    <studytitle>Pyronaridine-artesunate efficacy for the treatment of uncomplicated falciparum malaria in Cambodia</studytitle>
    <scientifictitle>Pyronaridine-artesunate efficacy for the treatment of uncomplicated falciparum malaria in Cambodia</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>071NECHR</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients with plasmodium falciparum infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>It is a single arm open label study to evaluation of the therapeutic efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated falciparum malaria. The eligible patients are treated with a daily dose of 1 tablet for 20-&lt;24kg, 2 tablets for 24-&lt;45 kg, 3 tablets for 45-&lt;65kg and 4 tablets for 65 and above over 3 days. One tablet contains 60mg artesunate+18mg pyronaridine. Each dose is administered orally under the supervision of the medical doctor. A dose is repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only. The patients has a blood smear examined daily during the first week by microscopy until parasite clearance (2 consecutive negative slides on two consecutive days; both asexual and sexual stages). The patients has a weekly appointment over 42 days. If the patient do not attend for the follow-up a home-visitor from the study team will try to locate the patient and bring them to the study site. </interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> The proportion of adequate clinical and parasitological response (ACPR) to the antimalarial treatment. A patient receives clinical examination and parastiological test for malaria on weekly basis over 42 days when the patient does not have malaria clinical manifestation and does not have malaria parasites in the blood the treatment outcome is classified as ACPR. </outcome>
      <timepoint>Day 42</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The blood samples were collected to monitor the hepatic biological values (ALT, AST, total and conjugated bilirubin and alkaline phosphatase). These values are to be obtainable on day 0, 3, 7, 14, 21, 28, 35 and 42 by a liver function test machine at each study site. </outcome>
      <timepoint>at day 0, 3, 7,14,21,28,35 and 42</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Adults and children with body weight of 20 kg or above
- Symptomatic of malaria infection, i.e. history of fever within 24  hours and/or presence of fever 37.5 degree celcius or above
- Microscopic confirmation of asexual stages of P. falciparum (P. falciparum and mixed infection in Pailin only) 
- Capability of taking an oral medication

</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Pregnancy or lactation (urine test for beta HCG to be performed on any woman of child bearing age, that is 18 to 45 years old)
- Female aged 12-18y
- Parasitemia less than 150 000/microlitre).
- Signs or symptoms indicative of severe malaria:
- Impaired consciousness (Blantyre Coma Score less than 5)
- Severe anaemia (Hct less than15%)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>- With the assumed efficacy of 90%, a sample size of 138 participants is needed for the study in three study sites for +/- 5% precision (this width is 0.1 in document), i.e., 85 to 95%. Allowing for a 5% drop out, we propose a sample size of 145 patients.

- KaplanMeier survival analysis
- Cox proportional hazards regression

</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>25/08/2014</anticipatedstartdate>
    <actualstartdate>27/08/2014</actualstartdate>
    <anticipatedenddate>30/01/2015</anticipatedenddate>
    <actualenddate>31/01/2015</actualenddate>
    <samplesize>145</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Cambodia</country>
      <state>Pailin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Cambodia</country>
      <state>Battambang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Cambodia</country>
      <state>Pursat</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>World Health Organization</primarysponsorname>
    <primarysponsoraddress>World Health Organization
20 Av. Appia, 1211 Geneva 27
</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Centre for Parasitology, Entomology and Malaria Control</fundingname>
      <fundingaddress>Corner St. 92, Trapeang Svay, Phnom Penh Thmey, Sen Sok, Phnom Penh
</fundingaddress>
      <fundingcountry>Cambodia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>The ministry of health</sponsorname>
      <sponsoraddress>No. 151-153, Kampuchea Krom Blvd (128), 12252 Phnom Penh</sponsoraddress>
      <sponsorcountry>Cambodia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Mahidol Oxford Tropical Research Unit (MORU)
Faculty of Tropical Medicine, Mahidol University                                             </othercollaboratorname>
      <othercollaboratoraddress>3/F 60th Anniversary Chalermprakiat Building, 420/6 Rajvithi Road, Rajthevee, Bangkok 10400, Thailand.                                                                                
                                                                                        </othercollaboratoraddress>
      <othercollaboratorcountry>Thailand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is to estimate the efficacy and safety of the treatment of plasmodium falciparum malaria with pyronaridine-artesunate over 42 day. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Ethics Committee for Health Research</ethicname>
      <ethicaddress>#2Blvd Kim Yl Sung, Khan Toul Kok, Phnom Penh</ethicaddress>
      <ethicapprovaldate>28/03/2014</ethicapprovaldate>
      <hrec>O71NECHR</hrec>
      <ethicsubmitdate>6/03/2014</ethicsubmitdate>
      <ethiccountry>Cambodia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/367427-Pyramax study 2014.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/367427-Ethics Approval Letter.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Rithea Leang</name>
      <address>National Centre for Parasitology, Entomology and Malaria Control Program
Corner St. 92, Trapeang Svay, Khan Sensok, Phnom Penh 
Thmey, Phnom Penh
Phone: 85512715666</address>
      <phone>+855 12 715 666</phone>
      <fax />
      <email>rithealeang@gmail.com</email>
      <country>Cambodia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Denis Mey Bouth</name>
      <address>National Centre for Parasitology, Entomology and Malaria Control Program
Corner St. 92, Trapeang Svay, Khan Sensok, Phnom Penh Thmey, Phnom Penh
</address>
      <phone>(+855 )12 858 320</phone>
      <fax>(+855) 23 996 202</fax>
      <email>mbdenis@yahoo.com</email>
      <country>Cambodia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Heng Pisal</name>
      <address>National Centre for Parasitology, Entomology and Malaria Control Program
Corner St. 92, Trapeang Svay, Khan Sensok, Phnom Penh Thmey, Phnom Penh</address>
      <phone>(+855) 23 996 202</phone>
      <fax />
      <email>hengpisal16@gmail.com</email>
      <country>Cambodia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>